AU2003294930B2 - Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same - Google Patents

Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same Download PDF

Info

Publication number
AU2003294930B2
AU2003294930B2 AU2003294930A AU2003294930A AU2003294930B2 AU 2003294930 B2 AU2003294930 B2 AU 2003294930B2 AU 2003294930 A AU2003294930 A AU 2003294930A AU 2003294930 A AU2003294930 A AU 2003294930A AU 2003294930 B2 AU2003294930 B2 AU 2003294930B2
Authority
AU
Australia
Prior art keywords
antibody
cells
pharmaceutical composition
seq
ncr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003294930A
Other languages
English (en)
Other versions
AU2003294930A1 (en
Inventor
Pascale Andre
Francois Romagne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of AU2003294930A1 publication Critical patent/AU2003294930A1/en
Application granted granted Critical
Publication of AU2003294930B2 publication Critical patent/AU2003294930B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003294930A 2002-12-23 2003-12-22 Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same Ceased AU2003294930B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43534402P 2002-12-23 2002-12-23
US60/435,344 2002-12-23
PCT/EP2003/014716 WO2004056392A1 (en) 2002-12-23 2003-12-22 Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same

Publications (2)

Publication Number Publication Date
AU2003294930A1 AU2003294930A1 (en) 2004-07-14
AU2003294930B2 true AU2003294930B2 (en) 2008-12-04

Family

ID=32682222

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003294930A Ceased AU2003294930B2 (en) 2002-12-23 2003-12-22 Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same

Country Status (6)

Country Link
US (1) US20080063717A1 (https=)
EP (1) EP1575615A1 (https=)
JP (1) JP2006514024A (https=)
AU (1) AU2003294930B2 (https=)
CA (1) CA2510787A1 (https=)
WO (1) WO2004056392A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US7803376B2 (en) * 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
WO2005105848A1 (en) * 2004-04-30 2005-11-10 Innate Pharma Compositions and methods for enhancing nk cell activity
EP3072522B1 (en) 2005-01-06 2019-04-24 Novo Nordisk A/S Anti-kir combination treatments and methods
AU2006340750B2 (en) 2005-11-28 2013-03-07 Zymogenetics, Inc. IL-21 antagonists
EP3103813A1 (en) 2007-12-07 2016-12-14 ZymoGenetics, Inc. Anti-human il-21 monoclonal antibodies
KR101133185B1 (ko) * 2008-07-29 2012-04-06 서울대학교병원 자연살해세포의 증식방법
SG10201603962TA (en) 2011-05-25 2016-07-28 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory disorders
JP5572863B2 (ja) 2011-06-24 2014-08-20 国立大学法人九州大学 Ｎｋ細胞の増幅方法
EP2947144B1 (en) * 2013-01-15 2020-09-09 Hiroyuki Abe Method for manufacturing immunocyte-containing composition, and cancer-treating composition
EP2824112B1 (en) 2013-07-10 2016-12-21 Miltenyi Biotec GmbH Method for inducing proliferation of Natural Killer cells by mobile nanomatrices
CN105462923B (zh) * 2014-12-17 2018-11-02 山东大学第二医院 一种人自然杀伤细胞体外高效扩增方法
JP6073417B2 (ja) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
IL274572B2 (en) 2015-07-16 2024-01-01 Biolinerx Ltd Compositions and methods for treating cancer
AU2016299166B2 (en) 2015-07-24 2022-03-31 Innate Pharma Methods for detecting tissue infiltrating NK cells
CN115925933A (zh) * 2015-12-28 2023-04-07 依奈特制药公司 NKp46结合蛋白的可变区
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CA3032249A1 (en) * 2016-08-17 2018-02-22 University Health Network Regulation of tumor-associated t cells
BR112019024556A2 (pt) 2017-05-24 2020-06-23 Novartis Ag Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN111304248B (zh) 2018-12-25 2021-08-24 百奥赛图江苏基因生物技术有限公司 人源化细胞因子il15基因改造非人动物的构建方法及应用
AU2020224681A1 (en) * 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
EP3927745A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
WO2020172601A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
WO2021143858A1 (en) * 2020-01-17 2021-07-22 Beigene, Ltd. ANTI-NKp30 ANTIBODIES AND METHODS OF USE
GB2612450A (en) 2020-04-24 2023-05-03 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
KR20230074487A (ko) 2020-08-26 2023-05-30 마렝고 테라퓨틱스, 인크. Trbc1 또는 trbc2를 검출하는 방법
CA3190755A1 (en) 2020-08-26 2022-03-03 Andreas Loew Multifunctional molecules that bind to calreticulin and uses thereof
AU2021331076A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
KR102581230B1 (ko) * 2020-10-16 2023-09-21 의료법인 성광의료재단 항암 관련 유전자 발현이 조절된 자연살해세포 및 이의 용도
KR102236011B1 (ko) * 2020-11-11 2021-04-05 한바이오 주식회사 Nk 세포의 대량증식 배양방법
US12345068B2 (en) 2021-11-19 2025-07-01 Sundance Spas, Inc. Self-maintaining hot tub or spa
US12473529B2 (en) 2023-07-18 2025-11-18 Nanotein Technologies, Inc. Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036630A2 (en) * 1999-11-15 2001-05-25 Innate Pharma S.A.S. Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979546B2 (en) * 1999-11-15 2005-12-27 Universita Di Genova Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036630A2 (en) * 1999-11-15 2001-05-25 Innate Pharma S.A.S. Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same

Also Published As

Publication number Publication date
CA2510787A1 (en) 2004-07-08
US20080063717A1 (en) 2008-03-13
EP1575615A1 (en) 2005-09-21
AU2003294930A1 (en) 2004-07-14
WO2004056392A1 (en) 2004-07-08
JP2006514024A (ja) 2006-04-27

Similar Documents

Publication Publication Date Title
AU2003294930B2 (en) Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same
Klingemann The NK-92 cell line—30 years later: its impact on natural killer cell research and treatment of cancer
JP7062720B2 (ja) 細胞免疫療法のための方法および組成物
EP3641768B1 (en) Chimeric Antigen Receptors (CARs), Compositions and Associated Methods
Revoltella et al. Granulocyte–macrophage colony-stimulating factor as an autocrine survival-growth factor in human gliomas
Petersen et al. Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists
Cooley et al. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu
EP4353750A2 (en) Chimeric antigen receptors (cars), compositions and methods thereof
Marin et al. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-ζ activating signal
US11945866B2 (en) Method of eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient using bi-specific antibodies
CA3145510A1 (en) Nk cell composition and preparations for immunotherapy and methods for their production
TW201713768A (zh) 嵌合抗原受體（ｃａｒ）、組合物及其使用方法
CA2133075A1 (en) CD28 Pathway Immunoregulation
Gao et al. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells
CN112771080B (zh) 针对steap1的嵌合受体及其使用方法
KR20190003456A (ko) 면역치료의 항-종양 활성을 높이기 위한 중간엽 줄기세포
US20240245771A1 (en) Fully human antibody for human b7h3, chimeric antigen receptor and uses thereof
US20040247594A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lack cd28
Yang et al. A novel activation pathway for mature thymocytes. Costimulation of CD2 (T, p50) and CD28 (T, p44) induces autocrine interleukin 2/interleukin 2 receptor-mediated cell proliferation.
Howells et al. Peripheral blood lymphocytes express the platelet‐type thrombin receptor
CA2404479A1 (en) Hybrid cytokine of il-7 and .beta.-chain of hepatocyte growth factor
KR20220119080A (ko) 치료용 종양-침윤 림프구들 배양을 위한 개선된 방법
Paganin et al. IL-4 inhibits binding and cytotoxicity of NK cells to vascular endothelium
AU2999299A (en) Methods and compositions for the selective expansion of gamma/delta t-cells
US20240207312A1 (en) Chimeric antigen receptor (car)-t cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired